Amarin Corp PLC ADR AMRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $13.93
- Day Range
- $13.92–14.35
- 52-Week Range
- $11.65–20.90
- Bid/Ask
- $13.26 / $15.24
- Shares Outstanding
- 20.97M
- Market Cap
- $297.76M
- Volume/Avg
- 82,121 / 67,849
Key Statistics
- Price/Earnings (Normalized)
- 15.77
- Price/Sales
- 1.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- —
- Total Number of Employees
- 80
- Website
- https://www.amarincorp.com
Valuation
|
Metric
|
AMRN
|
|---|---|
Price/Earnings (Normalized) | 15.77 |
Price/Book Value | 0.65 |
Price/Sales | 1.34 |
Price/Cash Flow | — |
Price/Earnings
AMRN
Financial Strength
|
Metric
|
AMRN
|
|---|---|
Quick Ratio | 2.31 |
Current Ratio | 3.48 |
Interest Coverage | — |
Quick Ratio
AMRN
Profitability
|
Metric
|
AMRN
|
|---|---|
Return on Assets (Normalized) | 0.76% |
Return on Equity (Normalized) | 1.09% |
Return on Invested Capital (Normalized) | −0.60% |
Return on Assets
AMRN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Blzwllxvb | Mrctw | $1T | |||
| Johnson & Johnson
JNJ
| Zvzprfnn | Dkwjt | $560B | |||
| AbbVie Inc
ABBV
| Czrbzfsvd | Cnxp | $401B | |||
| Roche Holding AG ADR
RHHBY
| Xxyphnspgc | Svbf | $330B | |||
| Merck & Co Inc
MRK
| Gfjnbmmq | Qkqr | $298B | |||
| AstraZeneca PLC
AZN
| Rndzzmcbx | Nsdm | $288B | |||
| Novartis AG ADR
NVS
| Xsvxmnjslp | Xsrs | $285B | |||
| Novo Nordisk AS ADR
NVO
| Tjjftgjtpz | Tsg | $195B | |||
| Amgen Inc
AMGN
| Wncsfxgfxg | Bxpgq | $189B | |||
| Gilead Sciences Inc
GILD
| Gykxxzwqj | Kphd | $160B |
United States